OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q4 2021. The put-call ratio across all filers is 1.20 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,303 | -39.6% | 22,071 | -0.8% | 0.00% | – |
| Q2 2023 | $114,789 | -4.8% | 22,246 | -2.7% | 0.00% | – |
| Q1 2023 | $120,530 | +74.6% | 22,871 | -6.9% | 0.00% | – |
| Q4 2022 | $69,030 | -17.8% | 24,566 | +22.2% | 0.00% | – |
| Q3 2022 | $84,000 | +1.2% | 20,095 | -2.3% | 0.00% | – |
| Q2 2022 | $83,000 | +20.3% | 20,571 | +46.6% | 0.00% | – |
| Q1 2022 | $69,000 | -24.2% | 14,035 | +7.7% | 0.00% | – |
| Q4 2021 | $91,000 | -93.8% | 13,036 | -91.1% | 0.00% | -100.0% |
| Q3 2021 | $1,458,000 | -29.2% | 145,741 | +0.4% | 0.00% | 0.0% |
| Q2 2021 | $2,059,000 | +325.4% | 145,200 | +391.7% | 0.00% | – |
| Q1 2021 | $484,000 | -22.9% | 29,529 | -2.8% | 0.00% | – |
| Q4 2020 | $628,000 | -72.3% | 30,365 | -43.8% | 0.00% | -100.0% |
| Q1 2015 | $2,268,000 | -22.2% | 54,000 | -56.5% | 0.00% | -40.0% |
| Q4 2014 | $2,916,000 | – | 124,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
| Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
| DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
| Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
| Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
| Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
| Covestor Ltd | 60,008 | $316 | 0.28% |
| Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
| EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
| Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |